Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019
Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019'; Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) pipeline Target constitutes close to 40 molecules. Out of which approximately 38 molecules are developed by companies and remaining by the universities/institutes.
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - RAR-related orphan receptor gamma (ROR?) is a protein encoded by the RORC gene. ROR? is member of the nuclear receptor family of transcription factors. It exist in two isoforms ROR? and ROR?t. ROR? is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R OR?t, appears to be highly restricted to the thymus. ROR? isoform is involved in the regulation of circadian rhythms and ROR?t plays an important regulatory role in thymopoiesis and in inhibiting apoptosis.
The report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019' outlays comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 20, 6 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Respiratory, Musculoskeletal Disorders, Dermatology, Metabolic Disorders and Ophthalmology which include indications Psoriasis, Rheumatoid Arthritis, Autoimmune Disorders, Inflammation, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Inflammatory Bowel Disease, Non-Alcoholic Steatohepatitis (NASH), Psoriatic Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Allergies, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Asthma, Bladder Cancer, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Encephalomyelitis, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Keratoconjunctivitis Sicca (Dry Eye), Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Metastatic Transitional (Urothelial) Tract Cancer, Neuromyelitis Optica (Devic’s Syndrome), Non-Small Cell Lung Cancer, Ovarian Cancer, Solid Tumor, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019'; Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) pipeline Target constitutes close to 40 molecules. Out of which approximately 38 molecules are developed by companies and remaining by the universities/institutes.
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - RAR-related orphan receptor gamma (ROR?) is a protein encoded by the RORC gene. ROR? is member of the nuclear receptor family of transcription factors. It exist in two isoforms ROR? and ROR?t. ROR? is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R OR?t, appears to be highly restricted to the thymus. ROR? isoform is involved in the regulation of circadian rhythms and ROR?t plays an important regulatory role in thymopoiesis and in inhibiting apoptosis.
The report 'Nuclear Receptor ROR Gamma - Pipeline Review, H2 2019' outlays comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 8, 20, 6 and 1 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Respiratory, Musculoskeletal Disorders, Dermatology, Metabolic Disorders and Ophthalmology which include indications Psoriasis, Rheumatoid Arthritis, Autoimmune Disorders, Inflammation, Multiple Sclerosis, Plaque Psoriasis (Psoriasis Vulgaris), Inflammatory Bowel Disease, Non-Alcoholic Steatohepatitis (NASH), Psoriatic Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Allergies, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Asthma, Bladder Cancer, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Encephalomyelitis, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Keratoconjunctivitis Sicca (Dry Eye), Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Metastatic Transitional (Urothelial) Tract Cancer, Neuromyelitis Optica (Devic’s Syndrome), Non-Small Cell Lung Cancer, Ovarian Cancer, Solid Tumor, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
- The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects
- The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones
Appendix
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones
Appendix
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Allergan Plc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2019
Pipeline by Biogen Inc, H2 2019
Pipeline by Boston Pharmaceuticals Inc, H2 2019
Pipeline by Brickell Biotech Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Celgene Corp, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Escalier Biosciences BV, H2 2019
Pipeline by Genentech Inc, H2 2019
Pipeline by Genfit SA, H2 2019
Pipeline by Glenmark Pharmaceuticals Ltd, H2 2019
Pipeline by Immunic Inc, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Lead Pharma Holding BV, H2 2019
Pipeline by Lycera Corp, H2 2019
Pipeline by Maruho Co Ltd, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Orphagen Pharmaceuticals Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Reata Pharmaceuticals Inc, H2 2019
Pipeline by SK Chemicals Co Ltd, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Visionary Pharmaceuticals Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Companies, H2 2019 (Contd..1)
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by AbbVie Inc, H2 2019
Pipeline by Allergan Plc, H2 2019
Pipeline by Amgen Inc, H2 2019
Pipeline by AstraZeneca Plc, H2 2019
Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H2 2019
Pipeline by Biogen Inc, H2 2019
Pipeline by Boston Pharmaceuticals Inc, H2 2019
Pipeline by Brickell Biotech Inc, H2 2019
Pipeline by Bristol-Myers Squibb Co, H2 2019
Pipeline by Celgene Corp, H2 2019
Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Pipeline by Escalier Biosciences BV, H2 2019
Pipeline by Genentech Inc, H2 2019
Pipeline by Genfit SA, H2 2019
Pipeline by Glenmark Pharmaceuticals Ltd, H2 2019
Pipeline by Immunic Inc, H2 2019
Pipeline by Johnson & Johnson, H2 2019
Pipeline by Lead Pharma Holding BV, H2 2019
Pipeline by Lycera Corp, H2 2019
Pipeline by Maruho Co Ltd, H2 2019
Pipeline by Novartis AG, H2 2019
Pipeline by Orphagen Pharmaceuticals Inc, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Reata Pharmaceuticals Inc, H2 2019
Pipeline by SK Chemicals Co Ltd, H2 2019
Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019
Pipeline by Visionary Pharmaceuticals Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Allergan Plc
Amgen Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Biogen Inc
Boston Pharmaceuticals Inc
Brickell Biotech Inc
Bristol-Myers Squibb Co
Celgene Corp
Daiichi Sankyo Co Ltd
Escalier Biosciences BV
Genentech Inc
Genfit SA
Glenmark Pharmaceuticals Ltd
Immunic Inc
Johnson & Johnson
Lead Pharma Holding BV
Lycera Corp
Maruho Co Ltd
Novartis AG
Orphagen Pharmaceuticals Inc
Pfizer Inc
Reata Pharmaceuticals Inc
SK Chemicals Co Ltd
Takeda Pharmaceutical Co Ltd
Visionary Pharmaceuticals Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Top 10 Molecule Types, H2 2019
Number of Products by Stage and Top 10 Molecule Types, H2 2019
COMPANIES MENTIONED
AbbVie Inc
Allergan Plc
Amgen Inc
AstraZeneca Plc
Aurigene Discovery Technologies Ltd
Beijing Hanmi Pharmaceutical Co Ltd
Biogen Inc
Boston Pharmaceuticals Inc
Brickell Biotech Inc
Bristol-Myers Squibb Co
Celgene Corp
Daiichi Sankyo Co Ltd
Escalier Biosciences BV
Genentech Inc
Genfit SA
Glenmark Pharmaceuticals Ltd
Immunic Inc
Johnson & Johnson
Lead Pharma Holding BV
Lycera Corp
Maruho Co Ltd
Novartis AG
Orphagen Pharmaceuticals Inc
Pfizer Inc
Reata Pharmaceuticals Inc
SK Chemicals Co Ltd
Takeda Pharmaceutical Co Ltd
Visionary Pharmaceuticals Inc
